| Net loss | -6.27M |
| Stock payable for acquired research and development | |
| Stock issued for acquired research and development | |
| Stock issued for services | |
| Stock issued for debt in excess of principal | |
| Amortization of discount on notes payable due to warrants and beneficial conversion feature | |
| Gain on extinguishment of debt | |
| Depreciation | |
| Amortization of debt financing costs | |
| Option expense | 485.96K |
| Loss on derivative instruments | |
| Loss on disposal of assets | 0 |
| Other current assets | 356.76K |
| Accounts payable - third parties and related parties | 278.56K |
| Accrued expenses | 91.48K |
| Net cash used in operating activities | |
| Purchase of property & equipment | -1.22K |
| Net cash used in investing activities | |
| Common stock and warrants sold for cash, net of offering costs | 276.91K |
| Common stock repurchased and canceled | |
| Proceeds from exercise of warrants and options | |
| Proceeds from debt | |
| Repayments on notes payable | -148.34K |
| Net cash provided by financing activities | |
| Net change in cash and cash equivalents | -6.77M |
| Cash and cash equivalents at beginning of period | 12.58M |
| Cash and cash equivalents at end of period | 5.81M |
| Income tax | |
| Interest | 2.35K |
| Issuance of common stock to Sportan shareholders | |
| Issuance of common stock for accrued interest | |
| Issuance of warrants to placement agent | |
| Conversion of notes payable to common stock | |
| Conversion of accrued liabilities to common stock | |
| Conversion of accounts payable to note payable | |
| Warrants | |
| Beneficial conversion feature | |
| Stock attached to notes | |
| Fair value of derivative instrument | |
| Derivative reclassified to equity | |
| Unpaid additions to property and equipment | |